Publications by authors named "Rilan Bai"

Claim this Profile
A
ADAR1 Promotes Invasion and Migration and Inhibits Ferroptosis via the FAK/AKT Pathway in Colorectal Cancer.
Dongsheng He, Chao Niu, Rilan Bai, Naifei Chen, Jiuwei Cui

Mol Carcinog· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of fatty acid synthase on tumor and progress in the development of related therapies.
Rilan Bai, Jiuwei Cui

Chin Med J (Engl)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune status and combined immunotherapy progression in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant tumors.
Dongsheng He, Rilan Bai, Naifei Chen, Jiuwei Cui

Chin J Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trials.
Yiqian Liu, Liyun Miao, Xiao Chen, Xiaoli Zhu, Yan Li, Rilan Bai

Medicine (Baltimore)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies.
Wenqian Li, Rilan Bai, Hanfei Guo, Jiuwei Cui

Chin Med J (Engl)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic strategies targeting metabolic characteristics of cancer cells.
Rilan Bai, Ying Meng, Jiuwei Cui

Crit Rev Oncol Hematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitochondrial immune regulation and anti-tumor immunotherapy strategies targeting mitochondria.
Rilan Bai, Jiuwei Cui

Cancer Lett· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies.
Ying Meng, Rilan Bai, Jiuwei Cui

Thorac Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted therapy combined with immunotherapy in patients with breast infiltrating ductal carcinoma with axillary lymph node metastasis of metaplastic SCC.
Rilan Bai, Lin Jia, Yangyang Gao, Xu Sun, Naifei Chen

Thorac Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives.
Rilan Bai, Wenqian Li, Jiuwei Cui

Cancer Biol Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing.
Rilan Bai, Jiuwei Cui

Front Immunol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy.
Rilan Bai, Jiuwei Cui

Front Immunol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
Ri-Lan Bai, Nan-Ya Wang, Ling-Ling Zhao, Yong-Fei Zhang, Jiu-Wei Cui

Hepatobiliary Pancreat Dis Int· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns.
Rilan Bai, Xiao Chen, Wei Song, Huimin Tian, Jiuwei Cui

J Cancer Res Clin Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma.
Xiang-Liang Liu, Ri-Lan Bai, Xiao Chen, Yu-Guang Zhao, Xu Wang

Chin Med J (Engl)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in novel molecular typing and precise treatment strategies for small cell lung cancer.
Rilan Bai, Lingyu Li, Xiao Chen, Yuguang Zhao, Wei Song

Chin J Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options.
Jiu-Wei Cui, Qing Zhou, Shun Lu, Ying Cheng, Jie Wang, Ri-Lan Bai

Transl Lung Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events.
Rilan Bai, Naifei Chen, Xiao Chen, Lingyu Li, Wei Song

Cancer Biol Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single Nucleotide Polymorphisms in Are Related to Breast Cancer Risk and Prognosis in the Northeastern Chinese Population.
Zheng Lv, Changgui Kou, Naifei Chen, Lin Jia, Xu Sun, Rilan Bai

Front Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A brand new era of cancer immunotherapy: breakthroughs and challenges.
Ri-Lan Bai, Nai-Fei Chen, Ling-Yu Li, Jiu-Wei Cui

Chin Med J (Engl)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors.
Rilan Bai, Lingyu Li, Xiao Chen, Naifei Chen, Wei Song

J Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer.
Wen-Qian Li, Ling-Yu Li, Ri-Lan Bai, Lei Qian, Nai-Fei Chen

Chin Med J (Engl)· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer.
Rilan Bai, Lingyu Li, Xiao Chen, Naifei Chen, Wei Song

Front Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of Cancer Resistance to Immunotherapy.
Rilan Bai, Naifei Chen, Lingyu Li, Nawen Du, Ling Bai

Front Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors.
Rilan Bai, Zheng Lv, Dongsheng Xu, Jiuwei Cui

Biomark Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis